H-YLMFLLRKI-OH
Ref. 3D-PP48277
| 1mg | 217.00 € | ||
| 10mg | 253.00 € | ||
| 100mg | 455.00 € |
Product Information
Peptide H-YLMFLLRKI-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-YLMFLLRKI-OH include the following: Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma W Zhong, X Zhang, M Zhao , J Wu , D Lin - Biomaterials Science, 2020 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/v1/d0bm00772b P-082: Delineating CDK9-regulated molecular events for the development of rationally derived multiple myeloma treatment strategies O Aksoy, J Lind, V Sunder-Plassmann - Myeloma and Leukemia, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2152265021022163 An overview on therapeutic efficacy and challenges of nanoparticles in blood cancer therapy J Wang, L Sheng, Y Lai, Z Xu - Journal of King Saud University-Science, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1018364722003639 O13-5 Rejuvenated BCMA-specific CD8alphabeta+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology J Bae, S Kitayama, Z Herbert , L Daheron - Annals of , 2023 - annalsofoncology.orghttps://www.annalsofoncology.org/article/S0923-7534(23)00974-2/abstract Immunotherapeutic application of induced pluripotent stem cell technology: Rejuvenated BCMA-specific CD8+T cells for multiple myeloma J Bae, S Kitayama, Z Herbert , L Daheron, N Munshi - Cancer Research, 2022 - AACRhttps://aacrjournals.org/cancerres/article/82/12_Supplement/6347/699510 Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8alphabeta+ T cells targeting multiple myeloma J Bae, S Kitayama, Z Herbert , L Daheron, K Kurata - Blood, 2024 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497123141607 Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8alphabeta+ T cells targeting multiple myeloma J Bae, S Kitayama, Z Herbert , L Daheron, K Kurata - Blood, 2024 - ashpublications.orghttps://ashpublications.org/blood/article-pdf/143/10/895/2217129/blood_bld-2023-020528-main.pdf P-083: Rejuvenated BCMA-specific CD8+ Cytotoxic T lymphocytes derived from induced pluripotent stem cells for treatment of Multiple Myeloma J Bae, S Kitayama, L Daheron, Z Herbert - Myeloma and Leukemia, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2152265021022175 Rejuvenated BCMA-Specific CD8+ Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells: Immunotherapeutic Application in J Bae, S Kitayama, L Daheron, Z Herbert , NC Munshi - Blood, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497121020656 BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical J Bae, N Parayath , W Ma, M Amiji , N Munshi - Leukemia, 2020 - nature.comhttps://www.nature.com/articles/s41375-019-0540-7 Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application J Bae, M Samur , P Richardson, NC Munshi - Leukemia, 2019 - nature.comhttps://www.nature.com/articles/s41375-019-0414-z 812 Development of BCMA-targeted immunotherapy using vaccine-induced antigen-specific memory CD8+ T cells for treating patients with multiple myeloma J Bae, D Keskin , Y Huang, S Rowell, S Nikiforow - J , 2022 - scholar.archive.orghttps://scholar.archive.org/work/tjpgexi6a5gp7n6xdi255krbie/access/wayback/https://jitc.bmj.com/content/jitc/10/Suppl_2/A847.full.pdf O10-3 Association between necitumumab skin toxicity and efficacy in squamous NSCLC: A pooled analysis from SQUIRE and JFCM H Yoshioka, S Watanabe - Annals of Oncology, 2023 - annalsofoncology.orghttps://www.annalsofoncology.org/article/S0923-7534(23)00971-7/abstract Recent advances in nanotherapeutics for multiple myeloma D Iannazzo , R Ettari , S Giofracaš , AH Eid , A Bitto - Cancers, 2020 - mdpi.comhttps://www.mdpi.com/2072-6694/12/11/3144 Nanoparticles to improve the efficacy of peptide-based cancer vaccines AL Tornesello , M Tagliamonte , ML Tornesello - Cancers, 2020 - mdpi.comhttps://www.mdpi.com/2072-6694/12/4/1049 LAG-3: recent developments in combinational therapies in cancer A Chavanton, F Mialhe, J Abrey - Cancer , 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cas.16205 Nanomedicine for immunotherapy targeting hematological malignancies: current approaches and perspective A Allegra , MD Gioacchino , A Tonacci , C Petrarca - Nanomaterials, 2021 - mdpi.comhttps://www.mdpi.com/2079-4991/11/11/2792
Chemical properties
Technical inquiry about: 3D-PP48277 H-YLMFLLRKI-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
